Obesity Reviews • August 2026
A prospective study of 186 adults on obesity pharmacotherapy: 83% of engaged participants remained adherent at three months, with conversations clustering around clinically significant moments between visits. Presented at the International Congress on Obesity 2026.
Read more →
Obesity Facts • May 2026
In an Irish obesity clinic, 83% of active users of nymble's behavioural companion remained adherent to GLP-1 therapy at three months, with 85% engagement and 1% program discontinuation. Presented at the 33rd European Congress on Obesity.
Read more →
Canadian Obesity Summit • March 2026
An oral presentation of aggregated data across 15,000+ eligible patient interactions: 83% of active users remained adherent to pharmacotherapy at three months, against roughly 40–50% under standard care. Presented at the Canadian Obesity Summit in Montréal.
Read more →